BidaskClub lowered shares of Repligen (NASDAQ:RGEN) from a hold rating to a sell rating in a research note published on Wednesday morning.

RGEN has been the topic of a number of other research reports. TheStreet cut shares of Repligen from a b- rating to a c rating in a research report on Monday, November 13th. CL King began coverage on shares of Repligen in a research report on Monday, November 13th. They issued a buy rating and a $41.00 price objective on the stock. Jefferies Group restated a hold rating and issued a $40.00 price objective on shares of Repligen in a research report on Thursday, October 19th. Zacks Investment Research upgraded shares of Repligen from a sell rating to a hold rating in a research report on Thursday, January 11th. Finally, JPMorgan Chase & Co. began coverage on shares of Repligen in a research report on Tuesday, December 5th. They issued an overweight rating and a $42.00 price objective on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. The company has an average rating of Buy and a consensus price target of $44.38.

Repligen (RGEN) opened at $30.92 on Wednesday. Repligen has a 52-week low of $29.56 and a 52-week high of $46.81. The stock has a market cap of $1,347.04, a PE ratio of 53.31, a price-to-earnings-growth ratio of 1.74 and a beta of 0.91.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Thursday, November 9th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.04. Repligen had a net margin of 16.93% and a return on equity of 7.57%. The firm had revenue of $36.58 million for the quarter, compared to analysts’ expectations of $35.69 million. During the same quarter in the previous year, the company earned $0.08 earnings per share. The company’s revenue for the quarter was up 48.2% compared to the same quarter last year. analysts forecast that Repligen will post 0.61 earnings per share for the current fiscal year.

In related news, VP Howard Benjamin sold 12,729 shares of the business’s stock in a transaction dated Thursday, December 14th. The shares were sold at an average price of $35.34, for a total transaction of $449,842.86. Following the transaction, the vice president now owns 36,554 shares in the company, valued at $1,291,818.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Anthony Hunt sold 8,970 shares of the business’s stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $35.95, for a total transaction of $322,471.50. Following the transaction, the chief executive officer now owns 83,613 shares in the company, valued at approximately $3,005,887.35. The disclosure for this sale can be found here. 1.50% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC purchased a new stake in Repligen in the third quarter worth about $180,000. PNC Financial Services Group Inc. grew its holdings in Repligen by 162.8% in the second quarter. PNC Financial Services Group Inc. now owns 5,635 shares of the biotechnology company’s stock worth $234,000 after purchasing an additional 3,491 shares during the period. Crossmark Global Holdings Inc. purchased a new stake in Repligen in the third quarter worth about $241,000. Profund Advisors LLC grew its holdings in Repligen by 4.7% in the second quarter. Profund Advisors LLC now owns 6,365 shares of the biotechnology company’s stock worth $264,000 after purchasing an additional 286 shares during the period. Finally, Brown Advisory Inc. purchased a new stake in Repligen in the third quarter worth about $310,000. Institutional investors own 83.34% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This news story was reported by Daily Political and is owned by of Daily Political. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.dailypolitical.com/2018/02/10/bidaskclub-downgrades-repligen-rgen-to-sell.html.

About Repligen

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.